Genmab — Maj 2021
-
-
Godt med opremsningen vedr. Asco.
-
Det var i vores ungdom Bulder.
-
"until completion of clinical proof of concept studies in multiple myeloma and diffuse large B-cell lymphoma" fra aftalen Bulder
-
-
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab -doesn't look like that will be an option for Isa...
https://www.nature.com/articles/s41408-021-00478-4 -
Jeg synes vældig godt om dette udsagn q/a kl. 15:34: Let us start with our own product candidates. There will be an important presentation on epco data from the initial Phase I/II study. This presentation will highlight the promise and success of our DuoBody platform..
-
Q&A med CEO Jan de Winkel fra Genmab d. 17. maj 2021 på Proinvestor.com
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind